Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Jasper Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Jeet Mahal, Principal Financial Officer (Form 8-K filed 2026-09-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Velan Capital Investment Management LP (filed 2026-08-17).
Who is behind it
Jasper Therapeutics, Inc.: incorporated in Delaware; business address in Redwood City, California; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-09-28).
Officers and directors, each with the role and the filing that names them:
- Herb Cross: Executive Officer (Form D, 2026-08-05)
- Jeet Mahal: Executive Officer, Director (Form D, 2026-08-05)
- Patrick Crutcher: Director (Form D, 2026-08-05)
- Thomas Wiggans: Director (Form D, 2026-08-05)
- Judith Shizuru: Director (Form D, 2026-08-05)
- Svetlana Lucas: Director (Form D, 2026-08-05)
- Kurt von Emster: Director (Form D, 2026-08-05)
- Wenru Song: Executive Officer (Form D, 2026-08-05)
- Gregory F. Keenan: Executive Officer (Form D, 2026-08-05)
- Matthew E. Ros: Director (Form D, 2026-08-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-17 | Velan Capital Investment Management LP | 9.9% |
| Schedule 13D/A, 2026-07-20 | Velan Capital Investment Management LP | 9.88% |
| Schedule 13G/A, 2026-07-10 | Integrated Core Strategies (US) LLC | 1.7% |
| Schedule 13G/A, 2026-05-12 | Morgan Stanley | 4.8% |
| Schedule 13G/A, 2026-05-08 | The Goldman Sachs Group, Inc. | 0.5% |
| Schedule 13G/A, 2026-05-08 | Soleus Capital Management, L.P. | 1% |
| Schedule 13G, 2026-02-25 | Integrated Core Strategies (US) LLC | 5.8% |
| Schedule 13D/A, 2026-02-18 | The Carlyle Group Inc. | 3.8% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-28 | Jeet Mahal | Principal Financial Officer | appointed | |
| Form 8-K, 2026-07-17 | Patrick Crutcher | Director | appointed | |
| Form 8-K, 2026-05-21 | Christian Nolet | departed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-08-05 | $132M | $132M |
Acquisitions reported on Form 8-K, Item 2.01: acquired Kira Pharmaceuticals (2026-07-17).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/jasper-therapeuticsLast updated 2026-10-18
Primary record: Schedule 13G, 2026-08-17 · Form D, 2026-08-05 · Form 8-K, 2026-09-28 · Form 8-K, 2026-07-17
Who owns Jasper Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/jasper-therapeutics